2 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow RAND: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone - Opioid-Related Disorders, Substance-Related Disorders | Phase 3 | Completed | Yih-Ing Hser | 140 | 2024-10-14 | 2026-04-29 |
| Maternal Depression Treatment in HIV evidence-based depression treatment - Depression | Phase 2 / Phase 3 | Completed | RAND | 391 | 2019-07-08 | 2024-11-15 |
Depression (1) · Narcotic-Related Disorders (1) · Opioid-Related Disorders (1) · Substance-Related Disorders (1)
Buprenorphine (1)
Uganda (1) · United States (1)
Glenn Wagner, PhD (1) · Larissa Mooney, MD (1) · Yih-Ing Hser, PhD (1)
PMID 31277180, PMID 36127627, PMID 36907945, PMID 39301593, PMID 40018208, PMID 40188047, PMID 41850520
UG1DA049435 (1)